CTRI/2021/01/030677已完成未知
A multicenter, randomized, open-label, two-way crossover study to assess inspiratory flow profiles generated with medication-free CIPLA Dry Powder Inhaler and medication-free Seretide Accuhaler in patients with Chronic Obstructive Pulmonary Disease (COPD).
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Cipla Ltd
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female subjects of any ethnic origin, aged 40 to <= 80 years
- •2. Subjects willing to provide signed and dated written informed consent voluntarily.
- •3. Subjects on stable symptoms of COPD since a month based on investigatorâ??s decision.
- •4. Based on investigatorâ??s decision, subjects who can inhale as deep and fast as they can through an In-checkTM dial.
- •Established diagnosis of COPD according to: The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 for at least 3 months prior to Screening and who meet the following criteria:
- •- Post-bronchodilator FEV1/ Forced vital capacity (FVC) ratio of <70 %
- •- Post-bronchodilator FEV1 (within 15-30 minutes following intake of 400 mcg salbutamol) within the following range: 50% <= FEV1 < 80% of the predicted value for age, height and sex using the formula of the ECSC using appropriate correction factors for race
- •- Post-bronchodilator FEV1 (within 15-30 minutes following intake of 400 mcg salbutamol) within the following range: 30% <= FEV1 < 50% of the predicted value for age, height and sex using the formula of the ECSC using appropriate correction factors for race
- •Very severe
- •- Post-bronchodilator FEV1 (within 15-30 minutes following intake of 400 mcg salbutamol) within the following range: FEV1 < 30% of the predicted value for age, height and sex using the formula of the ECSC using appropriate correction factors for race.
- •6. Female subjects of childbearing potential must use an adequate method of contraception (e.g., hormonal birth control, intrauterine device, barrier method plus a spermicidal agent) during the entire study
- •7. The smokers or ex-smokers having history of >= 10 pack years prior to screening
排除标准
- •1 Requirement for oral/injectable steroid therapy due to unstable disease within the last 2 months prior to screening
- •2 Significant lung/airway diseases other than COPD
- •3 Subjects who are not considered eligible after evaluation by investigator as per Covid-19 diagnostic protocol at site
- •4 Surgery of the respiratory tract/lung or significant deformity (e.g., lung, conducting airways, thorax or vertebral column deformities) that may cause persistent airflow limitation or altered lung volumes
- •5 Salbutamol intolerance or contraindication to salbutamol
- •6 Significant acute respiratory infections within the last 4 weeks or chronic viral, bacterial or fungal airway infections
- •7 Other chronic or clinically relevant acute infections
- •8 Neurological diseases affecting the neuro-muscular function or performance of respiratory muscles, e.g., such as Myasthenia Gravis or Amyotrophic Lateral Sclerosis
- •9 Any major chronic illness including but not limited to a diagnosis of non-skin cancer, cystic fibrosis, bronchiectasis, α-1 anti-trypsin deficiency, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, unstable arrhythmia, congestive heart failure, stroke, severe hypertension, uncontrolled insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, significant neurodevelopmental delay or behavioral disorders (excluding mild attention deficit hyperactivity disorder
- •10 History of diaphragm dysfunctions, diaphragm hernia or surgery
- •11 Drug or alcohol abuse which would interfere with the subjectâ??s compliance
- •12 Employee of study site, or spouse/partner or relative of an investigator or study staff
- •13 Anticipated non-availability for study visits/procedures
- •14 Surgery that can be considered as a planned intervention (e.g., cataract surgery) within the entire study period
- •15 Obvious mental or physical incapacity to follow study procedures and investigator instructions adequately or to correctly practice inhalation and to use devices for inhalation
- •16 Pregnant or nursing women
- •17 Severe concomitant disease which may have an impact on the study participation as assessed by investigator
- •18 Patients with any history of premature birth less than 33 weeks gestation or significant level of respiratory care including mechanical ventilation required as neonate affecting the respiratory tract or chronic lung diseases, which in the opinion of the investigator or designated study personnel at site may interfere with the study evaluation or optimal participation in the study
研究者
相似试验
招募中
不适用
The clinical trial to assess inspiratory flow profiles generated with medication-free CIPLA Dry Powder Inhaler and Seretide Accuhaler in healthy, moderate to severe asthma, moderate to severe chronic obstructive pulmonary disease patients.CTRI/2018/10/016022Cipla Ltd
进行中（未招募）
不适用
A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 µg bd delivered via a metered dose inhaler (MDI) (TEVA UK Ltd) with a reference beclometasone formulation via a reference MDI in children with mild to moderate asthmaShort-term lower leg growth rate in children with documented mild to moderate asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-007455-14-DKTEVA UK Ltd
进行中（未招募）
1 期
A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime.(PREDICTIVE-BMI study) - PREDICTIVE-BMI studyType 2 diabetesMedDRA version: 7.0Level: PTClassification code 10049746EUCTR2005-000976-42-ESovo Nordisk Pharma S.A.
招募中
1 期
Bioavailability study between Bortezomib for Injection 3.5 mg/0.2 mL and VELCADE 3.5 mg powder for solution for injection at a dose of 1.3 mg/m2CTRI/2020/06/025971Shilpa Medicare Limited
已完成
不适用
Bioavailability study of Bortezomib for Injection 3.5 mg/vial in patients with Multiple MyelomaCTRI/2019/03/018107Shilpa Medicare Limited6